This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vanda's Fanapt Falls Flat

Stocks in this article: VNDANVSTTNP.OB

SOUTH SAN FRANCISCO, Calif. ( TheStreet) -- Fanapt is falling flat.

First year sales of schizophrenia drug developed by Vanda Pharmaceuticals (VNDA) and sold by Novartis (NVS) totaled just $31.4 million, a fraction of what Fanapt was expected to bring in, according to analysts.

Even that $31 million in Fanapt sales for 2010 is artificially high because it includes $20 million in sales recorded in the March quarter, nearly all of which was inventory stocking. If you assume about $1.5 million in true user sales in the first quarter, Fanapt's "real" sales for the year just ended were probably around $12-13 million.

Titan Pharmaceuticals (TTNP.OB), which along with Vanda receives royalty payments from Novartis based on quarterly Fanapt sales, reported Friday that Fanapt revenue for the fourth quarter totaled $5.1 million.

That's just $200,000 more in Fanapt sales than Novartis was able to generate in the third quarter, suggesting promotional efforts to push the drug have stalled.

Novartis reported fourth-quarter and 2010 earnings Jan. 27, but didn't break out Fanapt sales because the tiny dollar amount is immaterial to its overall business.

Titan, in its Friday announcement, tried to defend Fanapt's growth stating that average weekly prescriptions in the fourth quarter increased to 1,876 from 1,449 in the third quarter.

Yet last October, Titan said weekly Fanapt prescriptions exiting the September quarter totaled 1,800. If that's true, it means average weekly prescriptions barely grew in the fourth quarter.

Vanda developed Fanapt and got the drug approved in May 2009. In October 2009, Novartis paid Vanda $200 million for the right to sell Fanapt in the U.S. The drug was launched in January. In the early months of Fanapt's launch, it became clear that doctors were slow to prescribe Fanapt, according to IMS prescription tracking data.

Last May, a negative-leaning summary of Fanapt's clinical data in schizophrenia was included in the seventh edition of the Manual of Clinical Psychopharmacology, published by the American Psychiatric Association. The authors of the manual raised concerns about Fanapt's dosing, side effects and high cost compared to other drugs used to treat patients with schizophrenia.

Fanapt's poor sales performance in 2010 stands in stark contrast to the bullish estimates proffered by analysts in the days before the drug's commercial launch. To cite one example, Jefferies drug analyst Corey Davis forecast 2010 Fanapt sales to hit $104 million, growing to $210 million in 2011 and $303 million in 2013.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs